Table 1. Patient Characteristics Overall and by Extent of Remnant Liver Ischemia (RLI).
| Characteristic | Total | RLI Grade ≤1 | RLI Grade ≥2 | P Value for RLI Grade ≤1 vs RLI Grade ≥2a |
|---|---|---|---|---|
| All patients | 202 | 152 | 50 | NA |
| Male:female | 118:84 | 88:64 | 30:20 | .79 |
| Age, median (range), y | 56 (27-87) | 55 (27-79) | 58 (33-87) | .12b |
| ASA I/II/III | 17/89/96 | 13/66/73 | 4/23/23 | .95 |
| Type 2 diabetes, No. (%) | 18 (8.9) | 16 (10.5) | 2 (4.0) | .16 |
| Hypertension, No. (%) | 95 (47.0) | 70 (46.1) | 25 (50.0) | .63 |
| Use of anticoagulant agent, No. (%) | 48 (23.8) | 36 (23.7) | 12 (24.0) | .96 |
| Primary tumor | ||||
| Colon-rectum | 161:41 | 120:32 | 41:9 | .64 |
| T1/T2-T3/T4 | 35:167 | 27:125 | 8:42 | .78 |
| Lymph node metastases, No. (%) | 125 (61.9) | 90 (59.2) | 35 (70.0) | .17 |
| Prehepatic resection chemotherapy, No. (%) | 168 (83.2) | 126 (82.9) | 42 (84.0) | .86 |
| ≤6 Cycles | 59 (35.1) | 42 (33.3) | 17 (40.5) | .40 |
| ≥2 Regimens | 15 (8.9) | 9 (7.1) | 6 (14.3) | .16 |
| Fluorouracil-based chemotherapy regimen | ||||
| Oxaliplatin | 134 (79.8) | 104 (82.5) | 30 (71.4) | .12 |
| Irinotecan hydrochloride | 29 (17.3) | 20 (15.9) | 9 (21.4) | .41 |
| Use of bevacizumab | 121 (72.0) | 94 (74.6) | 27 (64.3) | .20 |
| Use of anti-EGFR agent | 14 (8.3) | 10 (7.9) | 4 (9.5) | .75 |
| Major pathologic response | 84 (50.0) | 67 (53.2) | 17 (40.5) | .15 |
| Prehepatic resection laboratory value, median (range) | ||||
| Carcinoembryonic antigen, ng/mL | 3.8 (0.5-446) | 3.7 (0.5-446) | 4.2 (1.0-350) | .14b |
| Aspartate aminotransferase, U/L | 30 (12-99) | 31 (12-99) | 30 (14-99) | .63b |
| Platelet count, ×103/µL | 202 (93-690) | 204.5 (93-589) | 200.5 (111-690) | .93b |
| Potassium, mEq/L | 4.2 (3.5-5.7) | 4.2 (3.5-5.7) | 4.2 (3.5-5.4) | .91b |
| Lactate dehydrogenase, U/L | 485 (293-3155) | 483 (293-1431) | 492 (334-3155) | .32b |
| NLR before hepatic resection >5, No. (%) | 19 (9.4) | 14 (9.2) | 5 (10.0) | .87 |
| Portal vein embolization, No. (%) | 184 (91.1) | 138 (90.8) | 46 (92.0) | .79 |
| Hepatic resection | ||||
| Pringle maneuver, No. (%) | 163 (80.7) | 125 (82.2) | 38 (76.0) | .33 |
| Estimated blood loss, median (range), mL | 250 (45-3300) | 250 (50-3300) | 250 (45-1850) | .60b |
| Red blood cell transfusion, No. (%) | 17 (8.4) | 12 (7.9) | 5 (10.0) | .64 |
| Operative time, median (range), min | 235 (55-678) | 235 (55-678) | 263 (70-595) | .74b |
| Surgical procedure major-minor | 99:103 | 78:74 | 21:29 | .25 |
| Anatomic resection, No. (%) | 73 (36.1) | 61 (40.1) | 12 (24.0) | .04 |
| Liver metastases | ||||
| Synchronous- metachronous |
148:54 | 110:42 | 38:12 | .62 |
| Maximum tumor size, median (range), mm | 25 (5.0-120) | 24 (5.0-120) | 30 (6.0-105) | .16b |
| Solitary-multiple tumors, No. | 89:113 | 74:78 | 15:35 | .02 |
| Residual cancer R0-R1 | 185:17 | 137:15 | 48:2 | .20 |
| Well/moderately/poorly differentiated | 3/184/15 | 2/138/12 | 1/46/3 | .86 |
| Total morbidity, No. (%) | 125 (61.9) | 90 (59.2) | 35 (70.0) | .17 |
| Major complication with Clavien-Dindo grade ≥IIIa, No. (%) | 51 (25.2) | 33 (21.7) | 18 (36.0) | .04 |
| RAS status, No. (%) | ||||
| Wild type | 129 (63.9) | 101 (66.4) | 28 (56.0) | .18 |
| Mutant | 73 (36.1) | 51 (33.6) | 22 (44.0) | |
| Length of stay, median (range), d | 7 (3-37) | 7 (3-16) | 8 (4-37) | .006b |
| RLI grade, No. (%) | ||||
| 0, None | 105 (52.0) | 105 (69.1) | 0 | <.001 |
| 1, Marginal | 47 (23.3) | 47 (30.9) | 0 | |
| 2, Partial | 45 (22.3) | 0 | 45 (90.0) | |
| 3, Segmental | 5 (2.5) | 0 | 5 (10.0) | |
| 4, Necrotic | 0 | 0 | 0 | |
| Posthepatic resection chemotherapy, No. (%) | 184 (91.1) | 143 (94.1) | 41 (82.0) | .009 |
| Interval between hepatic resection and beginning of adjuvant chemotherapy, median (range), d | 56 (11-337) | 55 (11-337) | 60 (12-236) | .39b |
| NLR at 3 mo after hepatic resection >5 | 31 (15.3) | 16 (10.5) | 15 (30.0) | <.001 |
Abbreviations: ASA, American Society of Anesthesiologists’ physical status classification; EGFR, epidermal growth factor receptor; NA, not applicable; NLR, neutrophil to lymphocyte ratio.
SI conversion factors: To convert aspartate aminotransferase and lactate dehydrogenase levels to microkatals per liter, multiply by 0.0167; carcinoembryonic antigen level to micrograms per liter, multiply by 1.0; platelet count to ×109/µL, multiply by 1.0; and potassium level to millimoles per liter, multiply by 1.0.
a
By χ2 test unless indicated otherwise.
b
By Wilcoxon rank sum test.